EMA identifies gaps in industry preparedness for Brexit

July 10, 2018 – A recent European Medicines Agency (EMA) survey shows that marketing authorisation holders for more than half (58%) of the 694 centrally authorised products (CAP) with an important step in their regulatory processes in the United Kingdom (UK), are on track with their regulatory planning to ensure that their marketing authorisation remains valid once the UK leaves the European Union (EU). Regulatory authorities and marketing authorisation holders both play an … (leggi tutto)